Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexeo Therapeutics, Inc. - Common Stock (NQ: LXEO ) 11.15 -0.17 (-1.46%) Streaming Delayed Price Updated: 3:55 PM EDT, Jul 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Lexeo Therapeutics, Inc. - Common Stock Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights May 09, 2024 From Lexeo Therapeutics Via GlobeNewswire Lexeo Therapeutics to Participate in Upcoming Investor Conferences May 07, 2024 From Lexeo Therapeutics Via GlobeNewswire Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy April 22, 2024 From Lexeo Therapeutics Via GlobeNewswire Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy April 16, 2024 From Lexeo Therapeutics Via GlobeNewswire Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing March 13, 2024 Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP with participation from new and existing investors including RA Capital Management, Surveyor... From Lexeo Therapeutics Via GlobeNewswire Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights March 11, 2024 From Lexeo Therapeutics Via GlobeNewswire Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing March 11, 2024 Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management, Surveyor... From Lexeo Therapeutics Via GlobeNewswire Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments February 05, 2024 From Lexeo Therapeutics Via GlobeNewswire Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From LEXEO Therapeutics Via GlobeNewswire Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM) December 18, 2023 From LEXEO Therapeutics Via GlobeNewswire Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights December 11, 2023 From LEXEO Therapeutics Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
